Results 41 to 50 of about 9,464 (261)

Дизајн на физибилити студија за воспоставување на производство на zirconium-89 радиоизотоп и имплементација на 89Zr-радиофармацевтици во клиничката пракса во Република Северна Македонија [PDF]

open access: yes, 2023
In the last decade, the application of radiopharmaceuticals based on zirconium-89 (89Zr) radiometal has increased in both preclinical and clinical studies.
Angelovska, Bistra   +8 more
core   +2 more sources

Detection limit of 89Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI

open access: yesEJNMMI Research, 2020
Purpose Tracking cells in vivo using imaging can provide non-invasive information to understand the pharmacology, efficacy, and safety of novel cell therapies. Zirconium-89 (t 1/2 = 78.4 h) has recently been used to synthesize [89Zr]Zr(oxinate)4 for cell
Laura M. Lechermann   +13 more
doaj   +1 more source

89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors [PDF]

open access: yes, 2012
The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed in 20-30% of breast cancers and is associated with tumor growth, angiogenesis, and development of distant metastases.
Chang, Albert J.   +5 more
core   +3 more sources

Human Absorbed Dose Estimation of 89Zr-Anti-HER2 Complex Based on Animal Data [PDF]

open access: yesIranian Journal of Medical Physics
Introduction: This study aimed to estimate the radiation absorbed dose of human organs after injection of a high-potential PET radioimmunoconjugate of HER2+ breast cancers using the medical internal radiation dose (MIRD) method and the radiation dose ...
Hassan Yousefnia   +2 more
doaj   +1 more source

Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography

open access: yesMolecules, 2020
Glioblastoma multiforme (GBM) is the most aggressive glioma of the primary central nervous system. Due to the lack of effective treatment options, the prognosis for patients remains bleak.
Darpan N. Pandya   +6 more
doaj   +1 more source

PET Imaging of Acidic Tumor Environment With 89Zr-labeled pHLIP Probes

open access: yesFrontiers in Oncology, 2022
Acidosis of the tumor microenvironment is a hallmark of tumor progression and has emerged as an essential biomarker for cancer diagnosis, prognosis, and evaluation of treatment response.
David Bauer   +10 more
doaj   +1 more source

Apparatus and Experiments Towards Fully Automated Medical Isotope Production Using an Ion Beam Accelerator

open access: yesInstruments
Zirconium-89 (89Zr) is a widely used radionuclide in immune-PET imaging due to its physical decay characteristics. Despite its importance, the production of 89Zr radiopharmaceuticals remains largely manual, with limited cost-effective automation ...
Abdulaziz Yahya M. Hussain   +11 more
doaj   +1 more source

Application of Immuno-PET in Antibody–Drug Conjugate Development

open access: yesMolecular Imaging, 2018
Targeted therapies hold great promise for cancer treatment and may exhibit even greater efficacy when combined with patient selection tools. The clinical impact of identifying likely responders includes reducing the number of unnecessary and ineffective ...
Kendra S. Carmon PhD, Ali Azhdarinia PhD
doaj   +1 more source

Cyclotron production of high–specific activity 55Co and in vivo evaluation of the stability of 55Co metal-chelate-peptide complexes [PDF]

open access: yes, 2015
This work describes the production of high–specific activity 55 Co and the evaluation of the stability of 55 Co-metal-chelate-peptide complexes in vivo. 55 Co was produced via the 58 Ni(p,α) 55 Co reaction and purified using anion exchange chromatography
Bollinger, Elizabeth   +6 more
core   +3 more sources

Why are we failing to implement imaging studies with radiolabelled new molecular entities in early oncology drug development? [PDF]

open access: yes, 2014
In early drug development advanced imaging techniques can help with progressing new molecular entities (NME) to subsequent phases of drug development and thus reduce attrition.
Lahn, M   +3 more
core   +3 more sources

Home - About - Disclaimer - Privacy